Investigational Immunotherapy SRF231 Granted FDA Orphan Drug Status for Multiple Myeloma
The U.S. Food and Drug Administration has granted orphan drug status to SRF231 to treat multiple myeloma, according to Surface Oncology, which is developing…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
CHMP Recommends Darzalex Combo Therapy for Certain Newly Diagnosed Multiple Myeloma Patients
Expanded use of Darzalex (daratumumab) in combination with standard therapy for treating adult patients with newly-diagnosed multiple myeloma, and who are not candidates for stem cell…
Machine-learning Algorithm Predicts Responses to Myeloma Treatments
Inserting data from genetically similar patients into a machine-learning algorithm may help predict which multiple myeloma patients will benefit from Velcade (bortezomib) or Revlimid (lenalidomide)…
Urine Tests May Be Better Than Serum for Multiple Myeloma Screening, Study Suggests
Urine tests may be better than serum tests to diagnose multiple myeloma or its precursor conditions, because they can spot cases that…
Karyopharm Seeks Selinexor’s Accelerated Approval in US for Heavily Treated Myeloma Patients
Karyopharm Therapeutics is seeking accelerated approval for its investigational therapy selinexor in the United States as a treatment for heavily treated multiple myeloma…
Ninlaro Could Replace First-line Velcade in Older Myeloma Patients, Study Suggests
Older multiple myeloma patients who are unable to receive a stem cell transplant could receive Ninlaro (ixazomib) as part of their first line-therapy instead…
